Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seven New Drugs Approved In EU In First Two Months of 2018

Executive Summary

Seven products containing a new active substance were approved in Europe in the first two months of 2018: Shire's Adynovi and Roche/Chugai's Hemlibra for hemophilia A, Roche's Ocrevus for multiple sclerosis, Kyowa Kirin's Crysvita for hypophosphatemia, AstraZeneca's Fasenra for asthma, Novo Nordisk's Ozempic for diabetes, and MSD's Prevymis for prophylaxis of cytomegalovirus infection.
Advertisement

Related Content

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
Diurnal Adrenal Franchise Takes Shape With Alkindi Launch
More New EU Drug Approvals Bring Total For Year To 14
Diurnal's £11m Placing To Promote First Product Launch And Pipeline
Novo Nordisk To Target 'New GLP-1 Patients Only' With Weekly Ozempic
Seven Green Lights From EU’s CHMP, Including Drugs For Hemophilia, Diabetes, Alpha Mannosidosis And Hyperkalemia
All Systems Go as Roche MS Drug Ocrevus Secures EU Okay At Last
Semaglutide's CHMP Backing Stipulates Post-Approval Safety Studies

Topics

Advertisement
UsernamePublicRestriction

Register

PS122608

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel